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A covalent PIN1 inhibitor selectively targets cancer
cells by a dual mechanism of action
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The prolyl isomerase PIN1, a critical modiﬁer of multiple signalling pathways, is overexpressed
in the majority of cancers and its activity strongly contributes to tumour initiation and
progression. Inactivation of PIN1 function conversely curbs tumour growth and cancer stem
cell expansion, restores chemosensitivity and blocks metastatic spread, thus providing the
rationale for a therapeutic strategy based on PIN1 inhibition. Notwithstanding, potent PIN1
inhibitors are still missing from the arsenal of anti-cancer drugs. By a mechanism-based
screening, we have identiﬁed a novel covalent PIN1 inhibitor, KPT-6566, able to selectively
inhibit PIN1 and target it for degradation. We demonstrate that KPT-6566 covalently binds to
the catalytic site of PIN1. This interaction results in the release of a quinone-mimicking drug
that generates reactive oxygen species and DNA damage, inducing cell death speciﬁcally in
cancer cells. Accordingly, KPT-6566 treatment impairs PIN1-dependent cancer phenotypes
in vitro and growth of lung metastasis in vivo.
DOI: 10.1038/ncomms15772 OPEN
1 National Laboratory CIB (LNCIB), Area Science Park Padriciano, Trieste 34149, Italy. 2 Department of Life Sciences, University of Trieste, Trieste 34127, Italy.
3 Karyopharm Therapeutics, Newton, Massachusetts 02459, USA. 4Nerviano Medical Sciences Srl, Nerviano 20014, Italy. 5 Department of Science and Drug
Technology, University of Torino, Torino 10125, Italy. 6 Elettra Sincrotrone Trieste S.C.p.A., Area Science Park Basovizza, Trieste 34149, Italy. 7 Computational
Biomedicine, Institute for Advanced Simulation (IAS-5) and Institute of Neuroscience and Medicine (INM-9), Forschungszentrum Ju¨lich, Ju¨lich 52425,
Germany. 8 Ju¨lich Supercomputing Center (JSC), Forschungszentrum Ju¨lich, Ju¨lich 52425, Germany. 9Department of Oncology, Hematology and Stem Cell
Transplantation, University Hospital Aachen, RWTH Aachen University, Aachen 52074, Germany. 10 International Centre for Genetic Engineering and
Biotechnology (ICGEB), Area Science Park Padriciano, Trieste 34149, Italy. 11 IRCCS-Mario Negri Institute for Pharmacological Research, Milano 20156, Italy.
12 Department of Surgery, Oncology and Gastroenterology, Oncology and Immunology Section, University of Padova, Padova 35128, Italy. 13 Veneto Institute
of Oncology (IOV)-IRCCS, Padova 35128, Italy. * These authors contributed equally to this work. w Present addresses: Bioinformatics Core Facility, Center for
Integrative Biology (CIBIO), University of Trento, Trento 38123, Italy (S.P.); Pi Therapeutics, P.O.B. 4044, Ness Ziona 7403635, Israel (O.K.); Evogene Ltd.,
P.O.B. 2100, Rehovot 7612002, Israel (G.G.). Correspondence and requests for materials should be addressed to G.D.S. (email: delsal@lncib.it).
NATURE COMMUNICATIONS | 8:15772 | DOI: 10.1038/ncomms15772 | www.nature.com/naturecommunications 1
P
hosphorylation of proteins at serine or threonine residues
followed by proline (S/T-P) represents a common and
central signal transduction mechanism in many oncogenic
pathways and it is executed by a repertoire of proline-directed
kinases, for example, Cyclin-dependent kinases, and Mitogen
activated protein kinases, that fulﬁl key roles in controlling signal
transduction. Numerous oncogenes and tumour suppressors
either are directly regulated by and/or trigger signalling pathways
involving such phosphorylation events1.
In proteins, S/T-P motifs can adopt either a cis or a trans
conformation. Spontaneous conversion between isomers occurs
at a very slow rate and is further slowed down by phosphorylation
of these motifs. However, phospho-S/T-P sites can be recognized
by the peptidyl-prolyl cis/trans isomerase (PPIase) PIN1, which
catalyses cis-trans or trans-cis conformational changes around the
S-P or T-P bond. Among PPIases, PIN1 is the only enzyme able
to efﬁciently bind proteins containing phosphorylated S/T-P
sites1. Targeting of these motifs occurs in a modular fashion:
PIN1 ﬁrstly binds them through its WW domain, and then
catalyses their cis/trans isomerization through its catalytic PPIase
domain. Importantly, as a consequence of their modiﬁed
shape, PIN1 client proteins are profoundly affected in terms of
stability, subcellular localization, interaction with cellular partners
and occurrence of other post-translational modiﬁcations on
them2. Notably, PIN1 controls the ability of many transcription
factors to interact with their partners on gene promoters
and instructs transcription complexes towards speciﬁc gene
expression proﬁles3.
PIN1 has been shown to play a critical role during
oncogenesis4. It is overexpressed in the majority of cancers and
acts as a modulator of several cancer-driving signalling pathways,
including c-MYC, NOTCH1, WNT/b-catenin and RAS/MEK/
ERK pathways, while it simultaneously curbs several tumour
suppressors5. Work done by us has shown that PIN1 enables
a mutant p53 (mut-p53) pro-metastatic transcriptional program
and boosts breast cancer stem cells (CSCs) expansion through
activation of the NOTCH pathway6,7.
Genetic ablation of PIN1 reduces tumour growth and metastasis
in several oncogene-induced mouse models of tumorigenesis,
indicating the requirement for PIN1 for the development and
progression of some tumours4. In addition, PIN1 inhibition
sensitizes breast cancer cells to different targeted- and chemo-
therapies8–10 or overcomes drug resistance7,11. Accordingly, PIN1
inhibition alone has been recently shown to curb both leukaemia
and breast cancer stem cells by simultaneously dampening multiple
oncogenic pathways7,12,13. Altogether these data strongly indicate
that targeting PIN1 dismantles oncogenic pathway cooperation in
CSCs and non-CSC tumour cells, providing a rationale for the
development of PIN1 targeted therapies. A number of features,
including its well-deﬁned active site, its high speciﬁcity and its low
expression in normal tissues, make PIN1 an attractive target for the
design of small molecule inhibitors5,14. However, its small and
shallow enzymatic pocket, as well as the requirement of a molecule
with a negatively charged moiety for interfacing with its catalytic
centre have been challenging the design of PIN1 inhibitors14.
Although many molecules, mainly non-covalent inhibitors, have
been isolated so far, none of them has reached the clinical trial
phase because of their unsatisfactory pharmacological performance
in terms of potency, selectivity, solubility, cell permeability and
stability5,14.
In this work we describe a novel PIN1 inhibitor identiﬁed from a
library of commercial compounds we screened to isolate PIN1
inhibitors with increased biochemical efﬁciency based on a covalent
mechanisms of action15. The compound 2-{[4-(4-tert-butylbenzene-
sulfonamido)-1-oxo-1,4-dihydronaphthalen-2-yl]sulfanyl}acetic acid,
hereafter called KPT-6566 (1), turned out to selectively inhibit in vitro
the catalytic activity of PIN1. Structural, biochemical and
cell-based experiments allowed us to establish the mechanism of
action of this compound which, acting both as a covalent PIN1
inhibitor and as a PIN1-activated cytotoxic agent, is able to
speciﬁcally kill PIN1-proﬁcient tumour cells while leaving normal
cells unaffected.
Results
Structure- and mechanism-based screening for PIN1 inhibitors.
With the intent of isolating covalent inhibitors targeting the
cysteine C113 residue of PIN1 catalytic core, we screened a drug
like collection of 200,000 commercial compounds obtained from
several drug repositories (Fig. 1a). The compound pool was ﬁrst
ﬁltered applying the Lipinski’s rule of ﬁve criteria for enhanced
drug-likeness. Then, a virtual structure-based screening was
performed using the crystal structure of human PIN1 (PDB entry
2XPB)16. The compounds showing the higher docking scores
were then subjected to another virtual screening speciﬁcally
designed to identify compounds able to covalently target
the active site residue C113. To this aim, a covalent docking
approach using the CovDock-VS method17 was exploited. These
approaches yielded around one hundred possible PIN1 covalent
binders that were tested afterwards for cytotoxicity against
melanoma A375 cells using the MTT viability assay.
Non-transformed 3T3 cells were used as a control to make sure
hit compounds were not generally cytotoxic. Nine compounds
were selected for their differential toxicity between A375 and 3T3
cells (Supplementary Table 1) and were chosen for further
characterization as potential PIN1 inhibitors.
KPT-6566 inhibits PIN1 PPIase activity through covalent binding.
The compounds derived from the above screening were initially
tested for their capacity to inhibit the catalytic activity of
recombinant human PIN1 in a trypsin-coupled peptidyl-prolyl
isomerization assay (PPIase assay)18,19. The mutant PIN1
S67E protein was used as control of a reduced PPIase activity20.
The results show that, out of nine tested compounds, only
KPT-6566 (1) inhibited the PPIase activity of PIN1 (Fig. 1b) and
turned out to have an IC50 of 0.64 mM (Supplementary Table 2).
From a chemical point of view, KPT-6566 contains a polycyclic
aromatic hydrocarbon substituted with a sulfanyl-acetic acid
and a tert-butylphenylsulfonamide moiety (Fig. 1c), and it was
synthesized for subsequent analyses (Supplementary Methods).
To demonstrate whether KPT-6566 covalently binds to PIN1,
recombinant human PIN1 protein was analysed by mass
spectrometry following incubation with KPT-6566 or DMSO.
Liquid chromatography/mass spectrometry (LC/MS) analysis
revealed a 90Da increase of PIN1 molecular weight (MW) upon
treatment with KPT-6566 (Fig. 1d), indicating that a modiﬁcation
by addition of a sulfanyl-acetate group (-S-CH2-COOH) had
occurred. The þ 90Da adduct was not detected when C113 was
mutated to alanine (C113A, Supplementary Fig. 1a), indicating
that C113 was the target of this covalent modiﬁcation.
To conﬁrm the above results, PIN1 was incubated with
KPT-6566 or DMSO, and subjected to trypsin digestion. The
originated peptides were then analysed by Matrix-assisted laser
desorption ionization–time of ﬂight (MALDI-ToF-ToF) MS and
MS/MS. MS spectrum showed the presence of a peptide at
2213.9m z 1, corresponding to the S98–K117 peptide of
PIN1 bearing a þ 90Da MW increase (Supplementary Fig. 1b).
MS/MS fragmentation of the peptide at 2213.9m z 1 performed
with MALDI-ToF-ToF unambiguously conﬁrmed the identity
of the peptide and the presence of a 90Da adduct on C113
(Supplementary Fig. 1c). These MS analyses together indicate
the covalent addition of the 90Da sulfanyl-acetate group of
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KPT-6566 to the sulfur atom of C113, through a disulﬁde bond.
Accordingly, when the peptide-KPT-6566 mixture was incubated
with 100 mM of the reducing agent dithiothreitol (DTT), the
90Da adduct was not detected on the 2213.9m z 1 peptide,
conﬁrming that the sulfur atom of the sulfanyl-acetate moiety is
involved in a disulﬁde bridge with the -SH group of C113
(Supplementary Fig. 1b).
Next, to assess the mode of binding of KPT-6566 to PIN1, we
performed a molecular docking using Glide from the Schro¨dinger
suite21–23 (Supplementary Table 3). In accordance with MS
results, the best docking pose (Pose 1) obtained within this
analysis suggests that KPT-6566 positions itself into the catalytic
pocket of human PIN1 by creating (i) a hydrogen bond with the
side chains of K63 and R69, the active site residues mediating
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Figure 1 | KPT-6566 speciﬁcally inactivates PIN1 PPIase activity in vitro. (a) Scheme representing the screening conducted with the drug like collection,
indicating the stepwise approach that ends up with nine potential covalent inhibitors of PIN1. (b) Bar plot indicating PPIase activity K of PIN1 (black),
PIN1 S67E (white) and PIN1 with 30mM of the indicated compounds. Positive hit is marked in bold. (c) Chemical structure of KPT-6566 (1): the compound
contains a polycyclic aromatic hydrocarbon bound to a sulfanyl-acetic acid group (-S-CH2-COOH) and to a tert-butylphenyl group through a sulfonamide
moiety (N-SO2). (d) Mass spectrum deconvolution of DMSO (left) and KPT-6566 treated (right) PIN1. A MW increase of 90Da can be appreciated in the
compound treated sample. (e) 3D image showing the docking of KPT-6566 in the catalytic pocket of PIN1. KPT-6566 is shown in green licorice
representation. The surface of PIN1 is shown as solid representation and coloured by heteroatom. The binding cavity is magniﬁed in the right insert. (f) Plot
of the observed rate constants for inhibition (kobs) against inhibitor concentration of KPT-6566 from which estimations of kinetic parameters for covalent
inhibition of PIN1 in vitro were made. The corresponding kinact and Ki values are reported. (g) Bar plot indicating PPIase activity of GST-FKBP4 incubated with
DMSO, 30 mM FK506 or 30mM KPT-6566. (h) Same as in (g) for GST-PPIA incubated with DMSO, 30 mMCyclosporin A or 30 mM KPT-6566. Data shown
in b,g,h, are the means±s.d. of n¼ 3 independent experiments, *Po0.05, **Po0.01; two-tailed Student’s t-test.
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phosphate binding, and (ii) hydrophobic contacts with some
residues involved in the recognition of the proline substrate24.
Importantly, the electrophile sulfanyl-acetate moiety of the
compound directly faces the nucleophile sulfur atom of C113
(Fig. 1e and Supplementary Fig. 1d), which might lead to a
covalent complex formation as observed in the MS analyses.
Considering the covalent mechanism of action of KPT-6566,
we measured its potency as kinact/Ki ratio, where Ki describes
the afﬁnity of the initial non-covalent interaction and kinact
is the rate of the subsequent bond-forming reaction15. The
catalytic activity of PIN1 was measured in the presence of
increasing KPT-6566 concentrations at several time points after
preincubation (Fig. 1f and Supplementary Fig. 1e). Compared to
other covalent PIN1 inhibitors such as Juglone25, KPT-6566
shows a higher potency (kinact/Ki¼ 745.4min 1 nM 1) due to a
high kinact (0.466±0.05781min 1), despite its afﬁnity is in a
high nanomolar range (Ki¼ 625.2±324.7 nM) (Supplementary
Table 4).
Finally, to determine whether KPT-6566 selectively inhibits
PIN1 and not other PPIases, we measured the impact of
KPT-6566 on the PPIase activity of recombinant GST-FKBP4
and GST-PPIA, two isomerases also containing cysteine residues
and belonging to the FKBP and Cyclophilin families of PPIases26
(Supplementary Fig. 1f). Neither of these PPIases was affected by
KPT-6566, while, their speciﬁc inhibitors, FK506 and Cyclosporin
A (CsA) respectively, abolished their catalytic activity (Fig. 1g,h).
KPT-6566 impacts on PIN1 cellular functions. To assess
whether KPT-6566 could inhibit PIN1 function, we treated
immortalized ﬁbroblasts derived from wild-type (WT, Pin1þ /þ )
or Pin1 knockout (KO, Pin1 / ) mouse embryos (MEFs)6,27
with increasing amounts of KPT-6566, and monitored
cell proliferation. In WT MEFs KPT-6566 had a negative,
dose-dependent effect on proliferation (Fig. 2a) and induced a
decrease of hyperphosphorylated pRB and Cyclin D1 levels
(Fig. 2b). In Pin1 KO MEFs, instead, KPT-6566 treatment had no
effect on proliferation even at the highest dose, and the levels of
both Cyclin D1 and hyperphosphorylated pRB were unaffected
(Fig. 2a,b). Ectopic expression of HA-tagged PIN1 re-sensitized
Pin1 KO MEFs to KPT-6566 and, accordingly, Cyclin D1 levels
were decreased (Fig. 2c,d). In empty-vector expressing Pin1 KO
MEFs, instead, KPT-6566 had only a slight and statistically not
signiﬁcant effect on proliferation and no impact on Cyclin D1.
We next tested the effects of increasing doses of KPT-6566 on
an isogenic cell model constituted of (i) non-transformed
MCF10A mammary epithelial cells, which express lower levels
of PIN1 than cancer cell lines, and in which the enzyme is mainly
inactivated due to S71 phosphorylation12, and (ii) H-RasV12-
transformed MCF10AT1 cells28 which, instead, express high
levels of active PIN1 (Fig. 2e, left). Viability assays highlighted
that, consistent with the levels of PIN1, KPT-6566 was four times
more potent towards MCF10AT1 than towards MCF10A cells
(Fig. 2e, right and Supplementary Table 5).
To test whether sensitivity to KPT-6566 represents a common
trait of cancer cells with respect to normal cells, we treated cancer
cell lines of different origin and normal breast epithelial cells with
increasing doses of the drug and measured their viability. All
tested cancer cells expressed higher levels of PIN1 (Fig. 2f) and
were more sensitive to KPT-6566, even at low micromolar
concentrations (Fig. 2g).
KPT-6566 impacts on levels and function of PIN1 substrates.
PIN1 inﬂuences the turnover and activity of various proteins,
including Cyclin D1, p65 (NF-kB), c-JUN, NOTCH1 intracellular
domain (N1-ICD) and MCL-1 (ref. 2). To understand the impact
of KPT-6566 as a PIN1 inhibitor, we explored the effect of its
administration on these PIN1 targets in MDA-MB-231 cells.
The effect of KPT-6566 treatment on the levels of these
PIN1 client proteins was comparable to that observed following
PIN1 silencing (Fig. 3a and Supplementary Fig. 2a,b). We also
conﬁrmed downregulation of MCL-1 upon KPT-6566 treatment
in lung, prostate and pancreatic cancer cell lines (Supplementary
Fig. 2c).
To conﬁrm the above observations at a functional level, we
tested the effect of KPT-6566 on the activation of two pathways
that are controlled by PIN1, the mut-p53 and NOTCH1
pathways6,7. We evaluated the effect of KPT-6566 on the
transcription of a selection of mut-p53 and NOTCH1 target
genes. RT-qPCR analyses of MDA-MB-231 cells treated with
increasing concentrations of KPT-6566 showed a dose-dependent
decrease in their expression levels (Fig. 3b). This effect was
comparable to that observed upon PIN1 silencing (Suppleme-
ntary Fig. 2d). Altogether these data showed that, by inactivating
PIN1, KPT-6566 elicits the downregulation of PIN1 substrates
and of their target genes.
KPT-6566 impairs PIN1-dependent oncogenic phenotypes.
Next, we tested whether KPT-6566 interferes with colony forming
efﬁciency of transformed cells29,30. We ﬁrst assessed the IC50
of KPT-6566 by dose escalation studies in MDA-MB-231 cells
(Supplementary Fig. 3a). The IC50 for these experiments
turned out to be 1.2 mM. We used this concentration to treat
MDA-MB-231 cells transfected with control- or PIN1 siRNA
(Fig. 3c). Upon KPT-6566 treatment, we observed an inhibition
of colony formation in MDA-MB-231 cells transfected with
control siRNA. Similar inhibitory effects were obtained with
another PIN1 inhibitor, PiB31. Instead in PIN1 silenced cells,
which per se show a decreased colony forming efﬁciency,
KPT-6566 did not further affect colony number, while PiB
caused additional impairment of the colony forming efﬁciency,
indicating off-target effects of this compound31 (Fig. 3c). The
speciﬁc effect of KPT-6566 was conﬁrmed by using another
siRNA sequence (Supplementary Fig. 3b,c). Superimposable
results were also obtained with the prostate cancer cell line PC3
(Supplementary Fig. 3d–f). Altogether these data suggest that
KPT-6566 impairs colony formation through speciﬁc PIN1
inhibition.
Treatment of MDA-MB-231 and PC3 cancer cells with
KPT-6566 strongly impaired also the migratory and invasive
properties of these cells, while having only moderate effects on
proliferation in the short time-frame of the experiment (Fig. 3d
and Supplementary Fig. 3g).
KPT-6566 curbs self-renewal of breast cancer stem cells.
We and others have recently demonstrated that silencing or
inhibition of PIN1 impairs the maintenance of mammary CSCs
of both human and mouse origin7,13. To evaluate the impact
of KPT-6566 administration on breast CSCs maintenance,
secondary mammosphere (M2) formation assays were
performed in MDA-MB-231 cells. Cells were treated with
KPT-6566 or DMSO, prepared as single-cell suspensions and
grown in low-attachment conditions to form M2, as previously
done7. KPT-6566 treatment showed a signiﬁcant inhibitory
effect on M2 formation compared to DMSO (Fig. 3e and
Supplementary Fig. 3h). This result was further conﬁrmed by the
decrease of the CD44þ /CD24 /low/ESAþ breast CSC enriched
population32 and reduction of the levels of three different stem
cell markers33,34 following KPT-6566 treatment (Supplementary
Fig. 3i and Fig. 3f). To evaluate the requirement of PIN1 for
these effects, we tested the M2 formation efﬁciency (M2FE) of
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MCF10AT1 cells transduced with control- or PIN1 short hairpin
RNA (shRNA) expressing vectors, and treated with KPT-6566,
PiB, or DMSO. shPIN1 expressing cells showed a twofold
decrease in M2FE compared to control shRNA expressing cells
(Fig. 3g and Supplementary Fig. 3j,k). Treatment of control cells
with PiB or KPT-6566 caused a similar decrease of M2FE. In
contrast to PiB, KPT-6566 had no impact in PIN1 silenced cells,
further supporting a speciﬁc PIN1 inhibitory activity of this
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Figure 3 | KPT-6566 interferes with PIN1 oncogenic functions. (a) Immunoblotting of PIN1 client proteins expressed in MDA-MB-231 breast cancer cells
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Ctrl) or PIN1 silencing (shRNA PIN1), treated as indicated. (h) %M2FE of MCF10A cells transduced with empty- (Vec) or HA-PIN1-expressing vectors
(PIN1), treated as indicated. (a,f) Actin levels are reported as loading control; size markers are indicated. Data shown in b–e,g,h are the means±s.d. of
n¼ 3 independent experiments, *Po0.05, **Po0.01, n.s. not signiﬁcant; two-tailed Student’s t-test.
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compound. To conﬁrm this ﬁnding, we transduced MCF10A cells
with empty- or HA-tagged PIN1-expressing vectors, and tested
their M2FE. As already known, MCF10A cells per se have
a very low M2FE, but this feature can be enhanced by PIN1
overexpression, which also induces an enrichment of the
CD44high/CD24low cell population associated with stemness
traits7,35. This PIN1-dependent gain of function was abolished
by PiB and by KPT-6566 in a dose-dependent manner (Fig. 3h,
Supplementary Fig. 3l,m and Supplementary Table 6).
KPT-6566 promotes degradation of PIN1. Slowly dissociating
drugs, such as high afﬁnity or covalent binders that cause
structural changes of their target, have been shown to promote
target degradation36. Notably, we consistently observed that
KPT-6566 treatment of MEFs and human cancer cells caused a
decrease of endogenous PIN1 levels (Figs 2b and 4a). PIN1
promoter activity or PIN1 mRNA levels were only slightly
reduced following KPT-6566 treatment in MDA-MB-231 cells
(Supplementary Fig. 4a,b), likely due to the disruption of the
positive feed-forward loop existing between PIN1 and its
transcription factors27,29. We thus hypothesized that the effect
of KPT-6566 in reducing PIN1 levels mainly occurred through
protein degradation. The observed decrease in PIN1 protein was
similar to that obtained upon treatment with 20 mM all-trans-
retinoic acid (ATRA), another PIN1 inhibitor shown to target
PIN1 for degradation12. Instead, other PIN1 inhibitors, like
Juglone or PiB, did not impact on PIN1 protein levels (Fig. 4a),
as already observed by us and by others7,27,37. Moreover, upon
KPT-6566 treatment, same effects were observed on endogenous
PIN1 in cancer cell lines of different origins (Fig. 4b), and on
HA-tagged PIN1 protein ectopically expressed in PIN1 knockout
MDA-MB-231 cells (Fig. 4c). KPT-6566 affected PIN1 levels in
dose- and time-dependent manners (Fig. 4d,e), and by promoting
PIN1 proteasomal degradation, since addition of MG132, a
proteasome inhibitor, rescued the levels of both overexpressed
and endogenous PIN1 (Fig. 4f and Supplementary Fig. 4c).
This indicates that the covalent modiﬁcation of PIN1 induced by
KPT-6566 elicits structural changes leading to PIN1 degradation.
KPT-6566 elicits cellular responses to oxidative stress. MS data
suggest the transfer of the sulfanyl-acetate moiety of KPT-6566
to PIN1 C113 as a speciﬁc mode of action of this compound.
Hence, besides irreversibly blocking the PIN1 active site, a
remnant chemical species originates from KPT-6566 as a result
of the KPT-6566-PIN1 interaction. This species can be released
in the cellular compartment and interact with different
cellular molecules. We hypothesized that this byproduct
is 4-tert-butyl-N-(4-oxonaphthalen-1(4H)-ylidene)benzene-1-
sulfonamide (hereinafter referred to as KPT-6566-B (2), Supple-
mentary Methods). Containing a quinone-mimic substructure
with the potential to generate reactive oxygen species, both
KPT-6566 and KPT-6566-B may generate H2O2 in cells and
induce oxidative stress38. In addition, KPT-6566-B has also
features of a highly reactive electrophile that can engage different
nucleophilic species in the cell and form DNA adducts39
(Supplementary Fig. 5a).
To expand our observations regarding the action of KPT-6566
in cells, we compared the gene expression proﬁles of MDA-MB-
231 cells treated with KPT-6566 or with PIN1 RNAi, using an
Illumina microarray platform. Treatments with DMSO and with
control RNAi, respectively, were carried out as internal controls.
Unsupervised hierarchical cluster analysis of the expression
proﬁles of KPT-6566 and DMSO treated cells unveiled 499
signiﬁcantly modulated genes. In addition, 832 genes were
differentially expressed between PIN1- and control RNAi treated
cells. Comparison of the two lists of genes revealed similarities
between KPT-6566 and PIN1 RNAi treated cells. Indeed, 34% of
all genes downregulated by KPT-6566 were also downregulated
after PIN1 silencing (Fig. 5a and Supplementary Table 7).
However, KPT-6566 treatment also induced a peculiar
transcriptional program, since among its upregulated genes only
8% overlapped with those upregulated upon PIN1 silencing
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(Fig. 5a and Supplementary Table 8). To obtain more information
about the cellular processes affected by KPT-6566, we performed
Gene Ontology and Ingenuity Pathway Analysis (IPA). Both
analyses revealed a common enrichment for biological themes
and pathways connected to cell cycle and cell proliferation, as
expected for compounds targeting PIN1 in cancer cells4,
supporting the notion that part of the effect of KPT-6566 on
gene transcription is mediated by PIN1 inhibition (Fig. 5b,c and
Supplementary Table 9). We conﬁrmed this result by RT-qPCR
analysis of the expression of selected genes related to cell cycle
(Supplementary Fig. 5b and Supplementary Table 10). Strikingly,
IPA analysis revealed that, besides PIN1 inhibition, KPT-6566
elicits additional effects, in particular perturbing pathways related
to inﬂammation and oxidative stress response (Fig. 5c). These
pathways were predicted to be activated by KPT-6566 but not
modulated by PIN1 silencing. In line with the reactive nature of
KPT-6566 and KPT-6566-B, the NRF2-mediated oxidative stress
response, which physiologically represents one of the most
important, intracellular, antioxidant mechanisms40, emerged
among others as a pathway differentially regulated by KPT-
6566. We analysed several genes of this pathway and the
expression data demonstrated a good correlation with
microarray analyses (Fig. 5d). Altogether these analyses support
the notion that KPT-6566 acts on one hand as a PIN1 inhibitor,
and on the other as an inducer of cellular stress responses.
Given this premise and considering the induction of the
NRF2-dependent antioxidant response by KPT-6566, we analysed
ROS levels by CellROX FACS analyses in MDA-MB-231 and PC3
cells upon KPT-6566 administration. This analysis showed that
treatment with KPT-6566 increased endogenous ROS levels,
and this effect was drastically reduced by adding N-Acetyl-
Cysteine (NAC), a ROS scavenger and thiol group donor41
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(Supplementary Fig. 5c). A similar result was obtained by treating
MDA-MB-231 cells with KPT-6566-B (Supplementary Fig. 5d).
To investigate if KPT-6566 treatment elicits ROS formation
also in normal cells, we performed CellROX analyses in MCF10A
cells and observed an increase also in this cell type (Suppleme-
ntary Fig. 5c). However, in MCF10A cells the amount of ROS was
signiﬁcantly lower as compared to cancer cells and KPT-6566
treatment did not alter cell viability (Fig. 2g).
KPT-6566 induces DNA damage in a PIN1-dependent manner.
In addition to ROS production elicited by both KPT-6566
and KPT-6566-B, KPT-6566-B might be also involved in the
formation of DNA adducts due to its unsubstituted quinone-
mimic substructure. DNA adducts or ROS induced DNA damage
are either repaired and/or can be converted into double strand
breaks (DSBs)39,42. It is thus conceivable that treatment with
KPT-6566, once converted to KPT-6566-B, could induce
DNA damage thus evoking a DNA damage response (DDR)43.
To test this hypothesis, we analysed histone H2AX Ser139
phosphorylation (gH2AX), a marker of DNA damage43, in
MDA-MB-231 cells treated with KPT-6566 or KPT-6566-B. Both
compounds, indeed, elicited a dose-dependent increase of H2AX
phosphorylation (Fig. 6a and Supplementary Fig. 6a).
KPT-6566 treatment caused H2AX phosphorylation also in
other cancer cell lines, while normal immortalized MCF10A
breast cells did not show signs of DDR. Treatment with
Bleomycin, a radiomimetic known to induce DSBs, caused
H2AX phosphorylation in all cell lines, indicating that the
DDR mechanisms were intact (Fig. 6b and Supplementary
Fig. 6b).
We next asked whether KPT-6566 treatment caused DNA
damage in a PIN1-dependent manner. As show in Fig. 6c,d and
Supplementary Fig. 6c,d, PIN1 was required for the DNA
damaging activity of KPT-6566, but not of KPT-6566-B. In fact,
KPT-6566 treatment in MDA-MB-231 cells caused H2AX
phosphorylation and g-H2AX-positive foci formation in the
majority of cells. However, while KPT-6566 effect was almost
undetectable in PIN1 silenced cells (Fig. 6c,d and Supplementary
Fig. 6c), KPT-6566-B DNA damaging activity was independent
from PIN1, since the compound elicited H2AX phosphorylation
to a same extent in control and PIN1 silenced MDA-MB-231 cells
(Supplementary Fig. 6d). Accordingly, KPT-6566-B did not cause
any decrease in PIN1 levels in MDA-MB-231 cells
(Supplementary Fig. 6a,d).
Notably, other PIN1 inhibitors, such as ATRA, PiB or Juglone,
were not able to induce H2AX phosphorylation at the
concentrations generally used to inhibit PIN1 (Fig. 6e). These
results indicate that the presence of PIN1 is required for the DNA
damaging activity of KPT-6566, and demonstrate that KPT-6566
treatment elicits a PIN1-mediated intracellular release of
KPT-6566-B, causing DNA damage. This effect was partially
rescued by treatment with the highly efﬁcient ROS scavenger
melatonin44 (Supplementary Fig. 6e), suggesting that besides ROS
production, the release of KPT-6566-B might contribute to DNA
damage through formation of DNA adducts.
KPT-6566 induces cell death in cancer cells. Upon KPT-6566
administration, we observed DNA damage and killing effects
preferentially in cancer cells (Figs 2e,g and 6b). Tumour cells are
sensitive to DNA damage and depletion of antioxidant reservoirs,
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and, over a certain threshold, stress overload may lead to cancer
cell death45,46. Hence, we hypothesized that, upon KPT-6566
treatment, the observed acute increase of ROS and DNA damage
along with the effects of PIN1 inhibition, would represent the
coup de graˆce leading to proliferation arrest and cell death. To
assess whether KPT-6566 treatment impaired cancer cells
viability by inducing both proliferation arrest and cell death, we
performed a Trypan blue assay in control- or PIN1 silenced
MDA-MB-231 cells treated with DMSO or KPT-6566
(Supplementary Fig. 7a). As expected, PIN1 silencing caused
growth arrest27, but not cell death. KPT-6566 treatment caused
both a decrease in cell number and an increase of the number of
dead cells, indicating that, in addition to the proliferation arrest
associated with PIN1 inhibition, KPT-6566 also induced cell
death. Propidium Iodide/Annexin V FACS analyses conﬁrmed
these results, indicating that KPT-6566 induced cell death with
traits of late apoptosis and necrosis (Fig. 7a and Supplementary
Fig. 7b). We investigated this feature in cell lines from breast,
prostate, lung and pancreatic tumours by evaluating the presence
of cell death markers (PARP cleavage, cleaved Caspase-3, secreted
HMGB1)47 by western blot analysis (Fig. 7b and Supplementary
Fig. 7c). In line with the previous observations, all tested cell lines
showed markers of both apoptotic and necrotic cell death,
supporting a widespread killing activity of KPT-6566 towards
cancer cells.
Finally, we evaluated the effect of KPT-6566 in vivo and as a ﬁrst
step we tested its general toxicity in nude mice. At high doses of
the compound (60 or 90mgkg 1 injected intravenously) a strong
phlebitis was observed at the site of injection. Chronic intraper-
itoneal (i.p.) administrations of 30 and 45mgkg 1 of KPT-6566
were better tolerated, causing only local, non life-threatening
toxicity at the site of inoculation, where granulation and ﬁbrotic
thickening of the peritoneal wall were observed (personal
observations). On the basis of this result, we tested the effect of
a daily administration of 5mgkg 1 i.p. of KPT-6566 in a lung
colonization assay. To this aim, we performed tail vein injection of
MDA-MB-231 cells in nude mice (15 animals). The day after
cancer cell injection, mice were randomized in two groups to be
treated daily with either KPT-6566 or the vehicle. Twenty-seven
days after cancer cell inoculation, control mice began to show signs
of distress, as determined by body weight loss (Supplementary
Fig. 7d). Mice were killed and lungs were extracted and analysed
for metastatic growth by both metastatic area determination and
organ weight. The metastatic growth in KPT-6566 treated animals
was signiﬁcantly reduced compared to controls (Fig. 7c, and
Supplementary Fig. 7e). Interestingly, post mortem morphologic
analyses of vital organs did not reveal any sign of local or systemic/
organ toxicity.
Discussion
The prolyl isomerase PIN1 represents a critical player in several
signalling circuitries characterizing both CSCs and non-CSC
tumour cells. As a consequence of this function, PIN1 inhibition
causes the collapse of numerous oncogenic pathways at the same
time, making this isomerase an attractive drug target for the
development of treatments against aggressive and drug-resistant
cancers. Despite considerable efforts, however, poor success has
been reached so far: the available PIN1 inhibitors either lack the
required speciﬁcity and/or potency, or cannot efﬁciently enter
cells to inhibit PIN1 function in vivo.
Through a mechanism-based screening, we have identiﬁed a
novel PIN1 small molecule inhibitor (KPT-6566). KPT-6566 is
characterized by a unique mechanism of action, combining PIN1
inhibition with the release of a cytotoxic molecule. KPT-6566
blocks PIN1 catalytic activity by covalent interaction and elicits
PIN1 proteasome-dependent degradation. Moreover it represents
a selective inhibitor of PIN1, as it does not interact with other
thiol-containing PPIases.
Several PIN1 inhibitors have been identiﬁed so far with both
covalent and non-covalent mechanisms of action5,14. Among
them, ATRA, Juglone and PiB, have shown activity in cells and in
mouse models12,48,49. Our study indicates that KPT-6566 has a
number of advantages over these PIN1 inhibitors. As KPT-6566,
Juglone covalently interacts with PIN1 catalytic domain.
However, Juglone has a relatively simple structure that affects
its speciﬁcity. Indeed, Juglone has several off-targets and
manifests PIN1 independent activities14,50. Unlike Juglone or
PiB, which exerts its effects also through Parvulin 14 inhibition,
KPT-6566 is highly speciﬁc towards PIN1 and mainly ineffective
in cells deprived of PIN1. Like KPT-6566, also ATRA promotes
PIN1 degradation. Despite this and the advantage of being
an FDA approved drug, ATRA showed less potency towards
PIN1 than KPT-6566, likely due to its non-covalent mechanism
of action and its very short half-life12.
Most of all, however, KPT-6566 represents a one of a kind
PIN1 inhibitor because it associates a highly speciﬁc PIN1
inhibitory activity with the release of a reactive quinone-
mimicking byproduct that acts downstream of PIN1 and
generates DNA damage and elicits cancer cell death. Indeed, as
a PIN1 inhibitor and a ROS producing and DNA damaging
agent, KPT-6566 exerts both cytostatic and cytotoxic effects
(Fig. 7d). As a consequence of PIN1 inhibition and degradation,
KPT-6566 reduces levels and/or activity of several PIN1 client
proteins, such as Cyclin D1, c-JUN, MCL-1, N1-ICD, and
mut-p53. Although the effects on single client proteins are only
moderate, the simultaneous impairment of multiple PIN1 targets
may account for the observed strong suppression of all tested,
cancer-related phenotypes depending on PIN1 function, namely
proliferation, colony formation, invasion and CSC maintenance.
As a consequence of the release of a DNA damaging byproduct
and of ROS generation, KPT-6566 induces a signiﬁcant increase
of DNA damage and cell death speciﬁcally in cancer cells, while
only a slight increase of ROS levels in normal cells. Normal cells
express lower levels of PIN1 than cancer cells. This may account
for a slower kinetic of KPT-6566-B and DNA damage production
in these cells and for their limited sensitivity to KPT-6566
treatment. Moreover, normal cells are exposed to low levels of
oxidative stress. Cancer cells, instead, are characterized by
increased DNA damage and oxidative stress that make them
more vulnerable to agents causing further accumulation of
ROS and DNA damage45,46. Indeed, upon KPT-6566 treatment,
acute ROS overload along with a conspicuous increase of
DNA damage due to KPT-6566-B production causes cancer
cells death. Consistent with the pharmacological, biochemical and
anti-cancer properties observed in vitro, KPT-6566 chronic
administration in mice effectively reduced MDA-MB-231 lung
colonization without major toxicity. Further studies are required
to dissect the mechanisms involved in DNA damaging activity of
KPT-6566-B, such as adducts formation.
The mechanism of action of KPT-6566 meets the criteria of
modern rational drug design envisaging targeted delivery of drug
conjugates that release their cytotoxic counterparts speciﬁcally in
cancer cells51. Although additional structural modiﬁcations might
further improve KPT-6566 drug-likeness, its chemical features
and selectivity make it already an attractive molecule to be
developed for a potential use as an anti-cancer drug in humans.
Methods
Virtual screening. A library of commercial compounds was generated using a
drug like collection obtained from Asienx (www.asienx.com), Maybridge
(www.maybridge.com), Bionet (www.keyorganics.co.uk), Specs (www.specs.net),
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Chembridge (www.chembridge.com), ChemDiv (www.chemdiv.com) and Enamine
(www.enamine.net). Virtual Screening of this collection was performed using a
covalent docking approach suitable for large-scale virtual screening (VS) called
CovDock-VS method previously described17 on the structure of the catalytic
pocket of PIN1. Brieﬂy, compounds were prepared using the Virtual Screening
Workﬂow (VSW) ligand preparation tab in Maestro (Maestro v9.2. (2011)
Schro¨dinger, Inc., Portland). ‘Regularize input geometries’ was applied and
ionization states and tautomers were determined by the ionizer at a pH 7.4.
Compounds were subsequently ﬁltered in Canvas using the following chemical
property ranges that correspond to the Lipinski’s rule of ﬁve for enhanced
drug-likeness: MW 300–550, hydrogen-bond donors 0-5, hydrogen-bond acceptors
1–10, Rotatable bondso10, AlogPo5.5, Total charge -1a`1, PSA o140. The PIN1
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mice inoculated with MDA-MB-231 cells and treated with vehicle (n¼ 8) or KPT-6566 (n¼ 7); arrows indicate representative metastases. Scale bar, 4mm.
Right, computer-aided assessment of percentage of lung tissue area occupied by metastases in the indicated conditions. Data are reported in histograms as
means±s.e.m.; *Po0.05; two-tailed Mann–Whitney test. (d) Proposed model of KPT-6566 mechanism of action. After entering the cell, KPT-6566 binds
to PIN1 and elicits a cytostatic effect associated to covalent inhibition and degradation of PIN1 with consequent decrease of oncogenic circuitries. In
addition, KPT-6566 might induce intracellular ROS production (upper part). After reaction with PIN1, KPT-6566 has a simultaneous cytotoxic effect
releasing KPT-6566-B, which generates further ROS, induces DNA damage and cancer cell death (lower part).
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structure (PDBID: 2XPB)16 was used for structure-based screening following
protein preparation in Maestro (Maestro v9.2. (2011) Schro¨dinger, Inc., Portland).
In short, this included assignment of bond orders for ligands, addition of hydrogen
atoms, optimization of the hydrogen bonding network and a restrained
minimization. All default options were used.
Cytotoxicity tests. Mouse ﬁbroblast 3T3 and human malignant melanoma A375
cells were resuspended in DMEM cell culture medium containing 10% fetal bovine
serum (Gibco) and antibiotics (penicillin and streptomycin, Gibco). Hundred
microlitres per well was transferred to the assay plate (5,700 or 4,700 cells per well
for 3T3 and A375, respectively) and incubated overnight in a humidiﬁed incubator
at 37 C and 5% CO2. KPT compounds were serially diluted in assay media
(9 serial 1:3 dilutions) and 100 ml per well were added to the assay plate. Final assay
volume of each well was 200 ml, containing KPT compounds, starting from
30mM concentration downwards. After 70 h of incubation 20 ml of Promega
Substrate CellTiter 96 AQueous One Solution Cell Proliferation Assay Reagent were
added to each well and, according to the manufacturer’s procedures, after short
incubation at room temperature in a humidiﬁed chamber protected from light,
absorbance was read at 490 nm. Means of data collected in duplicate were plotted
on a logarithmic scale and IC50 values were obtained.
Protease coupled isomerization assay. Recombinant PIN1 protein, 0.5 nM, was
incubated in a 96-multi-well plate for 3 h at 0 C in 80ml HEPES buffer pH¼ 7.8 in
presence of 30 mM KPT compounds, or DMSO. In parallel, 0.5 nM bovine serum
albumin (BSA, PanReac Applichem) or PIN1 S67E were incubated with DMSO as
above. Immediately before measurement 15 ml of Trypsin 50mgml 1 (Sigma) and
5 ml of Suc-AEPF-MCA peptide 100 mgml 1 (ChemDiv) in TFE LiCl 480mM
were added and the solutions mixed. Hydrolysis of the substrate was monitored by
measuring the ﬂuorescence of the released MCA exciting at 370 nm and detecting
at 440 nm every 5 s for 5min using an EnSpire Perkin Elmer multiplate reader.
Normalized ﬂuorescence data were converted in Suc-AEPF-MCA concentration
values that were used to calculate the PPIase activity K following the method
described in Kullertz et al.52 using the value of BSA (k0) as reference of an
uncatalysed reaction. The same procedure was followed for GST-FKBP4 and
GST-PPIA PPIase assays using Suc-ALPF-MCA and Suc-AAPF-MCA peptides
(Bachem), respectively. Proteins were incubated with Cyclosporin A (Calbiochem
#239835), FK506 (Calbiochem #342500) or KPT-6566. Oligonucleotides for
construction of expressing vectors and recombinant protein production are
detailed in Supplementary Table 11 and in the Supplementary Methods section.
Determination of IC50 and inactivation constants in PPIase assays. For IC50
determination, human recombinant PIN1 was preincubated with different
concentrations of KPT-6566 and PPIase activity was measured after 180min.
K values of PPIase activity were plotted against inhibitor concentration in
a semi-logarithmic plot. IC50 values were calculated using log (inhibitor) vs.
normalized response function of GraphPad Prism software (GraphPad Software,
La Jolla, CA). For inactivation constants determination, human recombinant PIN1
was preincubated with different concentrations of KPT-6566 and PPIase activity
was measured after 0, 60, 120 or 180min. The logarithm of the percentage of the
remaining isomerization activity was plotted against preincubation time, yielding a
semi-logarithmic plot. The observed rate constant for inhibition, kobs, at each
concentration was determined from the slope of the semi-logarithmic plot of
inhibition vs. time. The kobs values were re-plotted against inhibitor concentration,
and ﬁtted to a hyperbolic equation (One site binding-hyperbola; GraphPad
Software), according to the equation kobs¼ kinact[I]/(Kiþ [I]), to obtain values for
Ki and kinact. k2 is the rate constant that deﬁnes the maximal rate of inactive
enzyme formation, I is the initial concentration of the inhibitor and Ki is the
inhibitor concentration when kobs¼ kinact/2. The kinact/Ki ratio represents the sec-
ond-order rate constant for the reaction of the inhibitor with the target.
LC/MS analysis. For LC-MS analyses KPT-6566 was dissolved in DMSO at a
concentration of 10mM. PIN1 samples were prepared in 30mM HEPES buffer
pH 7.9. PIN1 protein (10 mg) at a concentration of 9 mM was incubated with
threefold excess compound KPT-6566, in 100mM HEPES buffer pH 7.9 for 1 h in
ice. The reaction was stopped by adding 1 ml of 10% v/v TFA and the samples were
injected in the HPLC/MS instrument. WT PIN1 or the cysteine mutant C113A,
incubated with KPT-6566, KPT-6566 in combination with DTT, or in 2.7% DMSO
were analysed for full MW determination by liquid chromatography/electrospray
ionization mass spectrometry (LC/ESI-MS) using a 1100 HPLC apparatus coupled
through an API-ESI source to a 1946 MSD single quadrupole MS detector,
both from Agilent (Palo Alto, CA, USA). A RP Poroshell 300SB-C3 column
(2.1mm ID 75mm, 5 mm) was used and proteins were eluted applying
a 0.05% TFA/acetonitrile gradient. Acquired MS spectra were deconvoluted using
the ChemStation deconvolution software package (Agilent).
Protein digestion and MALDI-ToF-ToF MS and MS/MS analysis. PIN1 protein
was digested adding ProteaseMAX Surfactant Trypsin Enhancer (Promega
Corporation) (0.01% v/v ﬁnal concentration) and 1mg of TPCK trypsin to the
reaction solution. The mixture was incubated for 30min at 37 C. A volume of
0.3 ml of the samples were mixed with 0.3 ml of alpha-cyano-4-hydroxycinnamic
acid (HCCA) matrix (20mg in 1ml of 50% acetonitrile, 0.1% TFA) loaded on the
MALDI plate and analysed by 4800 MALDI ToF/ToF (ABI Sciex) in reﬂector
conditions using optimized parameters. Peptides at m/z possibly containing
modiﬁed cysteine were subjected to MS/MS analysis. Obtained spectra were
manually inspected to reconstruct the sequence.
Molecular-docking study. Computational studies were carried out using
Schro¨dinger suite running on a Linux based customized work station with CentOS
platform. Grid-Based Ligand Docking with Energetics (Glide) program was used
to analyse the binding conformations of KPT-6566 and PIN1 (ref. 21). Three-
dimensional (3D) structures of PIN1 (PDBID: 2XPB)16 were retrieved from the
Protein Data Bank (www.rcsb.org). The protein structures were organized using the
Protein Preparation Wizard, whereas the 3D structure of the ligand was optimized
using LigPrep module and the partial charges were ascribed using Optimized
Potentials for Liquid Simulations (OPLS3) force-ﬁeld53. Hydrogen atoms were added
to the protein structure to pH 7.0 considering the appropriate ionization states for
both the acidic and basic amino acid residues. The binding pocket of PIN1 was
deﬁned by a 10 10 10Å box centreed on the central position of C113. ‘Extra-
Precision’ (XP) mode of Glide application of Schro¨dinger suite helped to measure the
binding afﬁnity of proteins to ligand docking. The protocol facilitates ﬂexible ligand
docking within the rigid receptor and the best ligand pose with reference to the
protein was chosen based on the grading obtained by Glide Score23.
Cell lines and treatments. Unless otherwise stated, all cell lines were purchased
from ATCC or obtained from other laboratories cooperating on the project. Human
cell lines were subjected to STR genotyping with PowerPlex 18D System and their
identity was conﬁrmed comparing the results to reference ATCC, DMSZ and JCRB
databases and are not listed in the NCBI Biosample database of commonly
misidentiﬁed cell lines. They were also routinely tested for absence of Mycoplasma
infection by PCR/Immunoﬂuorescence. HMEC are normal hTERT immortalized
epithelial breast cells54. MCF10A are normal immortalized epithelial breast cells,
MCF10AT1 are xenograft-passaged T24 H-Ras transformed MCF10A cells28.
MDA-MB-231 and MDA-MB-468 are breast carcinoma cell lines, H1299 is a lung
carcinoma cell line, PC3 is a prostatic carcinoma cell line, LNCaP is a prostatic
carcinoma cell line derived from metastatic site, PANC1 is a pancreatic carcinoma
cell line, SKOV3 is a ovarian carcinoma cell line and HeLa is a human cervical
carcinoma cell line. PIN1 knockout MDA-MB-231 cells were generated by CRISPR/
Cas9 genome engineering technology, as described in Supplementary Method
section. Immortalized Pin1 / mouse ﬁbroblasts were obtained by spontaneous
immortalization from MEFs of C57BL6/129Sv mixed background and were already
described7. MDA-MB-231, MDA-MB-468, PANC1, SKOV3, HeLa and MEFs were
cultured in DMEM (BioWhittaker) supplemented with 10% fetal bovine serum (FBS,
Gibco), 100Uml 1 penicillin and 100mgml 1 streptomycin (Euroclone). H1299,
PC3 and LNCaP cells were grown in RPMI (BioWhittaker) supplemented with 10%
fetal bovine serum and penicillin/streptomycin. MCF10A and MCF10AT1 cells were
maintained in DMEM:F12 Ham’s (1:2) (BioWhittaker), supplemented with 5% horse
serum (Gibco), 10mgml 1 insulin (Sigma), 0.5mgml 1 hydrocortisone (Sigma)
and 20ngml 1 EGF (Cell Guidance System). HMEC cells were maintained in
MEBM (BioWhittaker), supplemented with 0.4% Bovine Pituitary Extract (Life
Technologies), 5mgml 1 insulin, 0.5mgml 1, hydrocortisone and 10ngml 1
EGF. Transient transfections were performed using standard procedures as already
described7,27. siRNA sequences are listed in Supplementary Table 12. For creation of
stable clones, a selection corresponding to the expressed vectors was applied for 2
weeks to transfected or infected cells at concentrations of 2mgml 1 for puromycin
(Sigma) and 5mgml 1 for blasticidin (InvivoGen). KPT-6566 (10mM) or
KPT-6566-B (5mM) dissolved in DMSO was used for cell treatments at the
indicated concentrations. Control cells received DMSO at the same concentrations
ranging from 0.05 to 0.01%. PPIase-Parvulin Inhibitor PiB (Calbiochem #529627),
Juglone (Calbiochem #420120), ATRA (all-trans-retinoic acid, Sigma R2625),
MG132 (Calbiochem #474790), NAC (N-Acetyl-L-Cysteine, Sigma A7250),
Melatonin (Sigma M5250) and Bleomycin (EURO Nippon Kayaku GmbH, Sanoﬁ
Aventis), were resuspended as indicated in the respective datasheets.
Immunoblotting and immunoﬂuorescence. For immunoblotting analyses protein
lysates were loaded and separated in SDS-PAGE, followed by Western blotting on
Nitrocellulose membranes (Amersham). Blocking was performed in Blotto-tween
(PBS, 0.2% Tween-20, not fat dry milk 5%) or with TBST (0.2% Tween-20,
Tris/HCl 25mM pH 7.5) plus 5% BSA (PanReac Applichem) depending on the
antibody, as described55. Immunoblot analyses were performed at least from three
biological replicates. For immunoﬂuorescence, after 48 h of treatment with the
compounds, cells were ﬁxed in 4% paraformaldehyde for 20min, washed in PBS,
permeabilized with Triton 0.1% for 5min and blocked in PBSþ FBS 1%þBSA
0.2% for 30min. Antigen recognition was done by incubating primary antibody for
1 h at 37 C and with goat anti-mouse Alexa Fluor 568 as secondary antibody for
30min at 37 C. Nuclei were counterstained with Hoechst 33342 (Life
Technologies). Representative ﬂuorescence images were taken with a  630
magniﬁcation on a Leica DM4000B microscope equipped with a LEICA DFC420C
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camera (Leica Microsystems S.r.l. Milan, Italy) and acquired with Leica Application
Suite 2.5.0 R1 (Leica Microsystems).
Quantitative real-time PCR (qRT-PCR) analysis. Total RNA from cell lines was
extracted with QIAzol Lysis Reagent (Qiagen) and cDNA was transcribed with
QuantiTect (Qiagen) in accordance with manufacturer’s protocols. cDNA was then
ampliﬁed on a CFX96 Touch Real-Time PCR Detection System with SsoAdvanced
SYBR Green Supermix (Biorad) and analysed with Biorad CFX Manager software.
Expression levels are always given relative to histone H3. Oligonucleotide
sequences are listed in Supplementary Table 10.
Proliferation assays. For proliferation curves, mouse embryo ﬁbroblasts were
seeded at a density of 5,000 cells per well in a 6-well plate and incubated for 24 h in
10% FBS-supplemented DMEM culture medium. Cells were then treated with
KPT-6566 or DMSO every second day. The number of cells was counted every
second day with hemocytometer after trypsin digestion.
For Trypan blue staining, cells were seeded at a density of 250,000 cells per well in
a 6-well plate and incubated for 24h in 10% FBS-supplemented DMEM culture
medium. Cells were then treated with KPT-6566 or DMSO. After 24 h the number of
cells was counted after trypsin digestion and staining with 0.2% Trypan Blue (Sigma).
Viability assays. For WST assay, MCF10A and MCF10AT1 cells were seeded in
96-multi-well plate at a concentration of 4,000 cells per well. Twenty-four hours
after seeding, cells were treated with the compound or DMSO as a negative control.
Forty-eight hours after compounds administration, growing medium was removed
and WST-1 was added to the cells (Promega). Absorbance was read in an
EnSpire Perkin Elmer multiplate reader. For ATPlite assay, cells were seeded in
96-multi-well view-plate at a concentration of 4,000 cells per well. Twenty-four
hours after seeding, cells were treated with the compound or DMSO as a negative
control. Forty-eight hours after compound administration, growing medium was
removed and cells were lysed with 50 ml of ATPlite 1step substrate solution (Perkin
Elmer), as described56. Luminescence was read in an EnSpire Perkin Elmer
multiplate reader. IC50 values were calculated using log (inhibitor) vs. normalized
response function of GraphPad Prism software.
Colony formation assay. Cells were seeded at a density of 5,000 (MDA-MB-231)
or 7,500 cells (PC3) per 6 cm diameter plate and incubated for 24 h in 10%
FBS-supplemented DMEM culture medium. Cells were then treated with
KPT-6566, PiB or DMSO. After 10 days, cells were ﬁxed in 4% formaldehyde
and stained with Giemsa (Sigma) diluted solution 1:10 in water for 2 h. Colonies
Z50 pixels were counted using ImageJ57 software after background subtraction.
Invasion assay. Invasion assays were performed by seeding cells at a density of
5,000 cells per well in 24-well PET inserts (8.0 mm pore size, Falcon) with matrigel-
coated ﬁlters. Cells were treated for 20 h with KPT-6566 or DMSO and then
invading cells were ﬁxed, stained with 0.5% Crystal Violet (Sigma) and counted
with a  20 objective on CK30 Olympus optical microscope (Olympus Italia Srl,
Milan, Italy).
Mammosphere cultures. To obtain mammospheres, cells from monolayer
cultures were enzymatically disaggregated (0.05% trypsin-EDTA, Gibco) to a
single-cell suspension, passed though a 40 mm cell strainer (BD Falcon), plated
at clonogenic density (2,500 cells cm 2), and grown in non-adherent culture
conditions, as described7. In detail, cells were grown for 7–10 days in DMEM:F12
(1:2) supplemented with B27 (Invitrogen Corporation, Carlsbad, CA, USA),
20 ngml 1 EGF (PROSPEC, East Brunswick, NJ, USA), 20 ngml 1 bFGF (BD
Biosciences, San Jose, CA, USA), 4 mgml 1 heparin (StemCell Technologies Inc.),
0.5 mgml 1 hydrocortisone (Sigma) and 5 mgml 1 Insulin (Sigma) in low
attachment 24- or 96-well plates (Corning) in a humiﬁed incubator at 37 C, 5%
CO2. Primary mammospheres (Z200mm) were obtained, collected, counted and
again enzymatically disaggregated as above to re-plate cells at clonogenic densities
to obtain secondary mammospheres. Percentages of mammosphere forming
efﬁciencies (%MFE) were calculated as number of mammospheres (Z200mm)
divided by the plated cell number and multiplied by a hundred. Mammospheres
were counted with a  20 objective on an Olympus CK30 microscope (Olympus
Italia Srl, Milan, Italy).
Flow cytometric analyses. FACS analyses of CD44/CD24/EpCAM surface
markers were performed as described7,32. Non-conﬂuent cell cultures were
trypsinized into single-cell suspension, counted, washed with phosphate-buffered
saline (PBS), and blocked in PBSþBSA 1%þEDTA 2mM. Staining with
antibodies was performed for 30min at 4 C and cells were analysed by BD
FACSCelesta Cell Analyzer (BD Biosciences). For CellROX analysis, cells were
treated with KPT-6566, NAC or DMSO. After 48 h, CellROX Green Reagent
(Thermo Fisher Scientiﬁc) was added at a ﬁnal concentration of 5 mM for 30min.
Cells were then washed, trypsinized and analysed by FACS. Mean ﬂuorescence
intensity was derived from each sample and the baseline ﬂuorescence was
calculated from the sample that was not incubated with CellROX reagent. For
Annexin V/Propidium Iodide analysis, Alexa Fluor 488 Annexin V/Dead Cell
Apoptosis Kit (Invitrogen) was used following the manufacturer’s protocols.
Analyses were performed on a FACSCalibur cell sorter (Becton Dickinson) and
data were analysed with FlowJo software for Mac (FlowJo, LLC 2013-2016).
Microarray hybridization and low level analysis. For gene expression proﬁling in
MDA-MB-231 cell lines, we used the Illumina HumanHT-12-v4-BeadChip
(Illumina). Total RNA isolated from the cell lines with control siRNA or PIN1 siRNA
or treated with DMSO or KPT-6566 for 48 h were reverse transcribed and ampliﬁed,
according to standard protocols and in vitro transcription was then carried out to
generate cRNA. cRNA was hybridized onto each array (three biological replicates for
the KPT-6566 condition and two for PIN1 siRNA condition) and then labelled with
Cy3-streptavidin (Amersham Biosciences). The array was then scanned using a
BeadStation 500 system (Illumina). The probe intensities were calculated and
normalized using GenomeStudio Data Analysis Software’s Gene Expression Module
(GSGX) Version 1.9 (Illumina). Further data processing was performed in the
R computing environment version 3.2 (http://www.r-project.org/), with
BioConductor packages (http://www.bioconductor.org/).
Functional annotation and pathway enrichment analysis. Full transcriptomic
expression data sets have been imported to IPA software (Qiagen,
www.ingenuity.com). P value and log fold-change cutoffs were applied in IPA as
reported in the text and ﬁgures. Pathway analysis module of IPA was further used
to associate analysed gene lists with molecular pathways (Fig. 5c). An independent,
parallel method for analysing the signatures was the pathway-related gene ontology
term enrichment analysis, using DAVID/EASE web tool with default parameters
and procedures (Fig. 5b and Supplementary Table 9).
Animal studies. Experiments were performed with 6-week-old female,
Hsd:Athymic Nude-Foxn1nu mice obtained from Envigo (Udine, Italy). Mice were
maintained under speciﬁc-pathogen-free conditions with constant temperature and
humidity, according to institutional guidelines. Animal experimentation was
conducted in conformance with the following laws, regulations and policies
governing the care and use of laboratory animals: Italian Governing Law
(D.lgs 26/2014; Authorization no. 19/2008-A issued March 6, 2008 by the Ministry
of Health). Mario Negri Institutional Regulations and Policies providing internal
authorizations for people conducting animal experiments (Quality Management
System Certiﬁcate–UNI EN ISO 9001:2008—Reg. N 6121); the NIH Guide for the
Care and Use of Laboratory Animals (2011 edition) and EU directives and
guidelines (EEC Council Directive 2010/63/UE), and in line with guidelines for the
welfare and use of animals in cancer research58. Animal experimental protocols
were reviewed and approved by the IRFMN Animal Care and Use Committee
(IACUC), which include ‘ad hoc’ members for ethical issues. Animals were housed
in the Institute’s Animal Care Facilities, which meet international standards and
were checked regularly by a certiﬁed veterinarian responsible for health
monitoring, animal welfare supervision, revision of experimental protocols and
procedures. For toxicity experiments mice (three for each group) were treated
(i) intravenous (i.v.) with vehicle (8% DMSO, 8% TWEEN80, 84% PBS) or 60 and
90mg kg 1 of KPT-6566 every 2 days for three times; (ii) i.p. with vehicle or 30
and 45mg kg 1 of KPT-6566 every 2 days for 2 weeks. For lung colonization
experiments mice were injected i.v. with 1 million of MDA-MB-231Luc6 cells.
After 1 day, mice were randomized in two experimental groups (at least seven mice
for each group) and treated i.p. with vehicle (4% DMSO, 4% TWEEN80, 92% PBS)
or KPT-6566 5mg kg 1, every day until killed (26 days of treatments). The
investigators were not blinded to group allocation during experiments and
outcome. During the study mice were monitored for parameters including
appearance and body weight. Mice were killed when they became moribund. Lungs
and other organs were collected, weighted and formalin ﬁxed for histological
analysis.
Histology and metastatic area determination. For lung metastases histology,
3 mm sections were cut from the lung lobes and stained with haematoxylin and
eosin. For computer-aided assessment of lung tissue, the area occupied by
metastatic foci, identiﬁable in sections of lung lobes, were calculated using a Leica
Aperio Digital Pathology Slide Scanner and the software Leica Aperio Image Scope,
summed and total value was ﬁnally compared to the whole area of the lung lobe.
Statistical analyses. The sample size was chosen to include at least three
biological replicates. No statistical method was used to predetermine the sample
size for animal studies. Experiments for which we showed representative images
were performed successfully at least three independent times. No samples or
animals were excluded from the analysis. Standard laboratory practice
randomization procedure was used for cell line groups and animals of the same age
and sex. The investigators were not blinded to allocation during experiments and
outcome.
Statistical tests were appropriately chosen for each experiment. For differentially
expressed genes from microarray experiments statistical analysis was performed
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms15772 ARTICLE
NATURE COMMUNICATIONS | 8:15772 | DOI: 10.1038/ncomms15772 | www.nature.com/naturecommunications 13
with limma and P values were adjusted for multiple testing using Benjamini and
Hochsberg’s method to control the false discovery rate. In the lung colonization
assay P value was determined using two-tailed Mann–Whitney tests and statistical
signiﬁcance was set at Po0.05. For all other experiments P values were determined
using two-tailed Student’s t-test and statistical signiﬁcance was set at Po0.05.
An estimation of the variation within each group of data was indicated by s.d., std.
error, s.e.m. or c.i. The variance was similar between groups that we compared.
Data availability. The authors declare that the main data supporting the ﬁndings
of this study are available within the article and its Supplementary Information
ﬁle. Full transcriptomic expression data sets are available at GEO database
(record GSE84909). Extra data are available from the corresponding author
on request.
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